✦ LIBER ✦

Excitotoxicity of l-DOPA and 6-OH-DOPA: Implications for Parkinson's and Huntington's diseases

✍ Scribed by John W. Olney; Charles F. Zorumski; Gregory R. Stewart; Madelon T. Price; Guangjian Wang; Joann Labruyere

Book ID: 115898569
Publisher: Elsevier Science
Year: 1990
Tongue: English
Weight: 1009 KB
Volume: 108
Category: Article
ISSN: 0014-4886
DOI: 10.1016/0014-4886(90)90134-e

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

L-DOPA AND JUVENILE HUNTINGTON'S DISEASE

✍ Barbeau, André 📂 Article 📅 1969 🏛 The Lancet 🌐 English ⚖ 182 KB

Neurochemical Responses to 6-Hydroxydopa

Neurochemical Responses to 6-Hydroxydopamine and L-Dopa Therapy: Implications for Parkinson's Disease

✍ MICHAEL J. ZIGMOND; TERESA G. HASTINGS; ELIZABETH D. ABERCROMBIE 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 873 KB

The Bereitschaftspotential, l-DOPA and p

The Bereitschaftspotential, l-DOPA and parkinson's disease

✍ J.P.R Dick; R Cantello; O Buruma; M Gioux; R Benecke; B.L Day; J.C Rothwell; P.D 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 899 KB

The pharmacology of Parkinson's disease:

The pharmacology of Parkinson's disease: l-dopa and beyond

✍ Peter Riederer; Gavin P. Reynolds; Kurt Jellinger 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 481 KB

L-dopa therapy for Parkinson's disease:

L-dopa therapy for Parkinson's disease: Past, present, and future

✍ Toshiharu Nagatsu; Makoto Sawada 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 122 KB

Dementia and treatment with L-dopa in Pa

Dementia and treatment with L-dopa in Parkinson's disease

✍ M. Hietanen; Dr. H. Teräväinen 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 536 KB

We compared the neuropsychological performance of patients with Parkinson's disease who were young at onset of the disease (mean age, 41.4 years) and had received prolonged L-dopa treatment (mean, 52.1 months) with nontreated patients of the same age. A similar comparison was made for patients who w